weekly_roundup
BioTechSign Daily Catalyst Roundup - November 14, 2026
Top BioTechSign catalyst names today: EYPT, GRFS, NKTR, ARGX, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 14, 2026
Daily Biotech Catalyst Digest: November 14, 2026
EYPT leads the current BioTechSign screen at 84.2/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| EYPT | EyePoint, Inc. | 84.2 | A | clinical activity 100%, short interest 70%, dilution risk 43% |
| GRFS | Grifols SA | 74.8 | B | publication signal 100%, clinical activity 100%, dilution risk 19% |
| NKTR | Nektar Therapeutics | 74.4 | B | publication signal 100%, short interest 90%, clinical activity 75% |
| ARGX | argenx SE | 74.0 | B | publication signal 100%, clinical activity 100%, dilution risk 15% |
| NUVB | Nuvation Bio | 73.6 | B | clinical activity 88%, PDUFA timing 75%, short interest 70% |
| BBIO | BridgeBio Pharma | 73.2 | B | PDUFA timing 100%, publication signal 100%, clinical activity 100% |
Recent Grade-Change Queue
- PBYI (Puma Biotechnology Inc) currently grades F with a 34.2/100 catalyst score. Main inputs: publication signal 100%, clinical activity 54%, short interest 50%.
- NSRX (Nasus Pharma Ltd.) currently grades D with a 36.1/100 catalyst score. Main inputs: clinical activity 58%, dilution risk 45%, publication signal 20%.
- SMMT (Summit Therapeutics Inc.) currently grades D with a 45.2/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, dilution risk 25%.
- QTTB (Q32 Bio Inc.) currently grades D with a 35.5/100 catalyst score. Main inputs: short interest 90%, dilution risk 48%, publication signal 35%.
- KRYS (Krystal Biotech) currently grades F with a 34.1/100 catalyst score. Main inputs: publication signal 70%, clinical activity 58%, short interest 50%.
- CRVS (Corvus Pharmaceuticals) currently grades D with a 37.9/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, dilution risk 68%.
- CUE (Cue Biopharma, Inc.) currently grades D with a 46.6/100 catalyst score. Main inputs: dilution risk 91%, short interest 70%, publication signal 65%.
- INBX (Inhibrx Inc) currently grades C with a 56.5/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, clinical activity 83%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.